Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04634825




Registration number
NCT04634825
Ethics application status
Date submitted
12/11/2020
Date registered
18/11/2020
Date last updated
20/12/2023

Titles & IDs
Public title
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Scientific title
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Secondary ID [1] 0 0
CP-MGA271-06
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Head and Neck Cancer 0 0
Head and Neck Neoplasms 0 0
Head and Neck Squamous Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Head and neck

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Enoblituzumab
Treatment: Other - Retifanlimab
Treatment: Other - Tebotelimab

Experimental: Retifanlimab Cohort - Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles

Experimental: Tebotelimab Cohort - Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles


Treatment: Other: Enoblituzumab
Anti-B7-H3 antibody

Treatment: Other: Retifanlimab
Anti-PD-1 antibody

Treatment: Other: Tebotelimab
PD-1 X LAG-3 bispecific DART molecule
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (ORR) of Enoblituzumab Plus Retifanlimab
Timepoint [1] 0 0
Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months.
Primary outcome [2] 0 0
Number of Patients With Adverse Events (AEs) Receiving Enoblituzumab Plus Tebotelimab
Timepoint [2] 0 0
Throughout the study, up to 16.5 months.
Primary outcome [3] 0 0
ORR of Enoblituzumab Plus Tebotelimab
Timepoint [3] 0 0
Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months
Secondary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months
Secondary outcome [2] 0 0
Disease-control Rate (DCR)
Timepoint [2] 0 0
Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months
Secondary outcome [3] 0 0
Duration of Response
Timepoint [3] 0 0
Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months
Secondary outcome [4] 0 0
Overall Survival
Timepoint [4] 0 0
up to 16.5 months
Secondary outcome [5] 0 0
Best Overall Response (BOR)
Timepoint [5] 0 0
Tumor assessment is conducted 6 weeks after first dose, then every 9 weeks until disease progression, up to 16.5 months
Secondary outcome [6] 0 0
Number of Patients With AEs Receiving Enoblituzumab Plus Retifanlimab
Timepoint [6] 0 0
Throughout the study, up to 16.5 months.
Secondary outcome [7] 0 0
Maximum Drug Concentration or Drug Concentration of Enoblituzumab at the End of Infusion of Enoblituzumab (Cmax)
Timepoint [7] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)
Secondary outcome [8] 0 0
Maximum Drug Concentration or Drug Concentration of Tebotelimab at the End of Infusion of Tebotelimab (Cmax)
Timepoint [8] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)
Secondary outcome [9] 0 0
Maximum Drug Concentration or Drug Concentration of Retifanlimab at the End of Infusion of Enoblituzumab (Cmax)
Timepoint [9] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)
Secondary outcome [10] 0 0
Trough Concentration of Enoblituzumab (Ctrough or Cmin)
Timepoint [10] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days
Secondary outcome [11] 0 0
Trough Concentration of Tebotelimab (Ctrough or Cmin)
Timepoint [11] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)
Secondary outcome [12] 0 0
Trough Concentration of Retifanlimab (Ctrough or Cmin)
Timepoint [12] 0 0
Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)
Secondary outcome [13] 0 0
Number of Patients Who Develop Antidrug Antibodies (ADA) to Enoblituzumab.
Timepoint [13] 0 0
Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months
Secondary outcome [14] 0 0
Number of Patients Who Develop ADA to Tebotelimab
Timepoint [14] 0 0
Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months
Secondary outcome [15] 0 0
Number of Patients Who ADA to Retifanlimab
Timepoint [15] 0 0
Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months

Eligibility
Key inclusion criteria
* Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) not curable by local therapy
* No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed > 6 months prior if given as part of multimodal treatment for locally advanced disease)
* Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Patients may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx (any histology)
* Availability of formalin-fixed, paraffin embedded tumor specimen or contemporary biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest
* Willing to consent for baseline and on-treatment biopsy.
* Performance status 0 or 1
* Life expectancy of 6 months or more
* Adequate end organ function
* At least one radiographically measurable lesion
* PD-L1 expression level that is either

1. Positive (combined positive score [CPS] = 1) for the retifanlimab cohort, or
2. Negative (CPS < 1) for the tebotelimab cohort
* Results available from human papilloma virus p16 status for oropharyngeal cancer
* Acceptable laboratory results
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Disease suitable for local therapy administered with curative intent
* Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN
* Radiation or other non-systemic therapy within 2 weeks prior to the first dose of study drug
* Prior therapy with an anti-B7-H3, anti-PD-1, anti-PD-L1, or anti-LAG-3 agent

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/03/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/07/2022
Sample size
Target
Accrual to date
Final
62
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Monash Health, Medical Oncology Department - Ruse
Recruitment hospital [3] 0 0
Royal North Shore Hospital - Sydney
Recruitment hospital [4] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [5] 0 0
Icon Cancer Centre Southport - Southport
Recruitment hospital [6] 0 0
Andrew Love Cancer Centre, Barwon Health - Geelong
Recruitment hospital [7] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
3168 - Ruse
Recruitment postcode(s) [3] 0 0
2065 - Sydney
Recruitment postcode(s) [4] 0 0
2298 - Waratah
Recruitment postcode(s) [5] 0 0
4215 - Southport
Recruitment postcode(s) [6] 0 0
3220 - Geelong
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Maryland
Country [2] 0 0
United States of America
State/province [2] 0 0
Michigan
Country [3] 0 0
United States of America
State/province [3] 0 0
Nevada
Country [4] 0 0
United States of America
State/province [4] 0 0
North Carolina
Country [5] 0 0
United States of America
State/province [5] 0 0
Pennsylvania
Country [6] 0 0
Bulgaria
State/province [6] 0 0
Dobrich
Country [7] 0 0
Bulgaria
State/province [7] 0 0
Panagyurishte
Country [8] 0 0
Bulgaria
State/province [8] 0 0
Pleven
Country [9] 0 0
Bulgaria
State/province [9] 0 0
Sofia
Country [10] 0 0
Hungary
State/province [10] 0 0
Budapest
Country [11] 0 0
Hungary
State/province [11] 0 0
Debrecen
Country [12] 0 0
Hungary
State/province [12] 0 0
Gyula
Country [13] 0 0
Hungary
State/province [13] 0 0
Szekszard
Country [14] 0 0
Poland
State/province [14] 0 0
Bialystok
Country [15] 0 0
Poland
State/province [15] 0 0
Gdansk
Country [16] 0 0
Poland
State/province [16] 0 0
Gliwice
Country [17] 0 0
Poland
State/province [17] 0 0
Jozefow
Country [18] 0 0
Poland
State/province [18] 0 0
Warszawa
Country [19] 0 0
Spain
State/province [19] 0 0
Badajoz
Country [20] 0 0
Spain
State/province [20] 0 0
Barcelona
Country [21] 0 0
Spain
State/province [21] 0 0
Madrid
Country [22] 0 0
Spain
State/province [22] 0 0
Pamplona
Country [23] 0 0
Spain
State/province [23] 0 0
Sevilla
Country [24] 0 0
Ukraine
State/province [24] 0 0
Dnipro
Country [25] 0 0
Ukraine
State/province [25] 0 0
Kharkiv
Country [26] 0 0
Ukraine
State/province [26] 0 0
Kropyvnytskyi
Country [27] 0 0
Ukraine
State/province [27] 0 0
Kyiv
Country [28] 0 0
Ukraine
State/province [28] 0 0
Sumy
Country [29] 0 0
Ukraine
State/province [29] 0 0
Vinnytsia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
MacroGenics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Trial website
https://clinicaltrials.gov/study/NCT04634825
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ashley L. Ward, MD
Address 0 0
MacroGenics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04634825